These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 35087746)

  • 1. Adaptive MR-Guided Stereotactic Radiotherapy is Beneficial for Ablative Treatment of Lung Tumors in High-Risk Locations.
    Regnery S; Buchele C; Weykamp F; Pohl M; Hoegen P; Eichkorn T; Held T; Ristau J; Rippke C; König L; Thomas M; Winter H; Adeberg S; Debus J; Klüter S; Hörner-Rieber J
    Front Oncol; 2021; 11():757031. PubMed ID: 35087746
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of On-Table Plan Adaptation in MR-Guided Ablative Radiation Therapy for Central Lung Tumors.
    Finazzi T; Palacios MA; Spoelstra FOB; Haasbeek CJA; Bruynzeel AME; Slotman BJ; Lagerwaard FJ; Senan S
    Int J Radiat Oncol Biol Phys; 2019 Jul; 104(4):933-941. PubMed ID: 30928360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of different dose accumulation strategies to estimate organ doses after stereotactic magnetic resonance-guided adaptive radiotherapy.
    Regnery S; Leiner L; Buchele C; Hoegen P; Sandrini E; Held T; Deng M; Eichkorn T; Rippke C; Renkamp CK; König L; Lang K; Adeberg S; Debus J; Klüter S; Hörner-Rieber J
    Radiat Oncol; 2023 May; 18(1):92. PubMed ID: 37248504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In Silico Trial of MR-Guided Midtreatment Adaptive Planning for Hypofractionated Stereotactic Radiation Therapy in Centrally Located Thoracic Tumors.
    Henke LE; Kashani R; Hilliard J; DeWees TA; Curcuru A; Przybysz D; Green O; Robinson CG; Bradley JD
    Int J Radiat Oncol Biol Phys; 2018 Nov; 102(4):987-995. PubMed ID: 29953910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of Daily Plan Adaptation in MR-Guided Stereotactic Ablative Radiation Therapy for Adrenal Metastases.
    Palacios MA; Bohoudi O; Bruynzeel AME; van Sörsen de Koste JR; Cobussen P; Slotman BJ; Lagerwaard FJ; Senan S
    Int J Radiat Oncol Biol Phys; 2018 Oct; 102(2):426-433. PubMed ID: 29902559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stereotactic magnetic resonance-guided online adaptive radiotherapy of adrenal metastases combines high ablative doses with optimized sparing of organs at risk.
    Hoegen P; Katsigiannopulos E; Buchele C; Regnery S; Weykamp F; Sandrini E; Ristau J; Liermann J; Meixner E; Forster T; Renkamp CK; Schlüter F; Rippke C; Debus J; Klüter S; Hörner-Rieber J
    Clin Transl Radiat Oncol; 2023 Mar; 39():100567. PubMed ID: 36935853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dosimetric Benefit of Adaptive Magnetic Resonance-Guided Stereotactic Body Radiotherapy of Liver Metastases.
    Weykamp F; Katsigiannopulos E; Piskorski L; Regnery S; Hoegen P; Ristau J; Renkamp CK; Liermann J; Forster T; Lang K; König L; Rippke C; Buchele C; Debus J; Klüter S; Hörner-Rieber J
    Cancers (Basel); 2022 Dec; 14(24):. PubMed ID: 36551527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Feasibility of Adaptive MR-guided Stereotactic Body Radiotherapy (SBRT) of Lung Tumors.
    Padgett KR; Simpson GN; Llorente R; Samuels MA; Dogan N
    Cureus; 2018 Apr; 10(4):e2423. PubMed ID: 29872603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Magnetic resonance guided adaptive stereotactic body radiotherapy for lung tumors in ultracentral location: the MAGELLAN trial (ARO 2021-3).
    Regnery S; Ristau J; Weykamp F; Hoegen P; Sprengel SD; Paul KM; Buchele C; Klüter S; Rippke C; Renkamp CK; Pohl M; Meis J; Welzel T; Adeberg S; Koerber SA; Debus J; Hörner-Rieber J
    Radiat Oncol; 2022 May; 17(1):102. PubMed ID: 35614486
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of online adaptive MR-guided stereotactic body radiotherapy of liver cancers.
    Padgett KR; Simpson G; Asher D; Portelance L; Bossart E; Dogan N
    Phys Med; 2020 Sep; 77():54-63. PubMed ID: 32781388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stereotactic ablative radiotherapy for ultra-central lung tumors: prioritize target coverage or organs at risk?
    Murrell DH; Laba JM; Erickson A; Millman B; Palma DA; Louie AV
    Radiat Oncol; 2018 Apr; 13(1):57. PubMed ID: 29606150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simulated daily plan adaptation for magnetic resonance-guided liver stereotactic body radiotherapy.
    Taylor E; Lukovic J; Velec M; Shessel A; Stanescu T; Dawson L; Létourneau D; Lindsay P
    Acta Oncol; 2021 Feb; 60(2):260-266. PubMed ID: 33170058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dosimetric benefit of online treatment plan adaptation in stereotactic ultrahypofractionated MR-guided radiotherapy for localized prostate cancer.
    Fink CA; Buchele C; Baumann L; Liermann J; Hoegen P; Ristau J; Regnery S; Sandrini E; König L; Rippke C; Bonekamp D; Schlemmer HP; Debus J; Koerber SA; Klüter S; Hörner-Rieber J
    Front Oncol; 2024; 14():1308406. PubMed ID: 38425342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. To fly or not to fly: Stereotactic MR-guided adaptive radiotherapy effectively treats ultracentral lung tumors with favorable long-term outcomes.
    Regnery S; Katsigiannopulos E; Hoegen P; Weykamp F; Sandrini E; Held T; Deng M; Eichkorn T; Buchele C; Rippke C; Renkamp CK; König L; Lang K; Thomas M; Winter H; Adeberg S; Klüter S; Debus J; Hörner-Rieber J
    Lung Cancer; 2023 May; 179():107175. PubMed ID: 36965207
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimization of treatment planning workflow and tumor coverage during daily adaptive magnetic resonance image guided radiation therapy (MR-IGRT) of pancreatic cancer.
    Olberg S; Green O; Cai B; Yang D; Rodriguez V; Zhang H; Kim JS; Parikh PJ; Mutic S; Park JC
    Radiat Oncol; 2018 Mar; 13(1):51. PubMed ID: 29573744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stereotactic MR-Guided Online Adaptive Radiation Therapy (SMART) for Ultracentral Thorax Malignancies: Results of a Phase 1 Trial.
    Henke LE; Olsen JR; Contreras JA; Curcuru A; DeWees TA; Green OL; Michalski J; Mutic S; Roach MC; Bradley JD; Parikh PJ; Kashani R; Robinson CG
    Adv Radiat Oncol; 2019; 4(1):201-209. PubMed ID: 30706029
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigation of Isotoxic Dose Escalation and Plan Quality with TDABC Analysis on a 0.35 T MR-Linac (MRL) System in Ablative 5-Fraction Stereotactic Magnetic Resonance-Guided Radiation Therapy (MRgRT) for Primary Pancreatic Cancer.
    Hawranko R; Sohn JJ; Neiderer K; Bump E; Harris T; Fields EC; Weiss E; Song WY
    J Clin Med; 2022 May; 11(9):. PubMed ID: 35566712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simulated Online Adaptive Magnetic Resonance-Guided Stereotactic Body Radiation Therapy for the Treatment of Oligometastatic Disease of the Abdomen and Central Thorax: Characterization of Potential Advantages.
    Henke L; Kashani R; Yang D; Zhao T; Green O; Olsen L; Rodriguez V; Wooten HO; Li HH; Hu Y; Bradley J; Robinson C; Parikh P; Michalski J; Mutic S; Olsen JR
    Int J Radiat Oncol Biol Phys; 2016 Dec; 96(5):1078-1086. PubMed ID: 27742541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of Monte Carlo algorithm for compliance with RTOG 0915 dosimetric criteria in peripheral lung cancer patients treated with stereotactic body radiotherapy.
    Pokhrel D; Sood S; Badkul R; Jiang H; McClinton C; Lominska C; Kumar P; Wang F
    J Appl Clin Med Phys; 2016 May; 17(3):277-293. PubMed ID: 27167284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stereotactic MR-guided adaptive radiation therapy for peripheral lung tumors.
    Finazzi T; Palacios MA; Haasbeek CJA; Admiraal MA; Spoelstra FOB; Bruynzeel AME; Slotman BJ; Lagerwaard FJ; Senan S
    Radiother Oncol; 2020 Mar; 144():46-52. PubMed ID: 31710943
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.